Human dosimetry and tumor kinetics of 111In CHX-A" DTPA trastuzumab in solid tumors using gamma-camera imaging

摘要: 1469 Objectives Trastuzumab (Herceptin™), targets HER2 on the surface of cancer cells and is used in treatment breast cancers that over-express HER2; however, it has also been demonstrated other malignancies express HER2. was radiolabeled with 111In via a CHX-A” DTPA bifunctional chelator (111In HER2) human biodistribution studies were performed patients solid tumors. This imaging agent may be useful determining tumors which respond to Herceptin™, identifying metastases, monitoring response or establishing dosimetry for future radioimmunotherapy. Methods To date, 6 HER positive (tumor size >2.5cm) have undergone gamma-camera (+/-SPECT/CT) at multiple time points following i.v. injection 4.8 mCi, ( Results The only adverse event observed self limiting Gr1 taste disturbance. Dosimetry estimates showed liver receiving highest dose, 2.66rads/mCi, followed by lower upper large intestines (1.32 0.85rads/mCi, respectively). ED 0.47rem/mCi. All enrolled date FISH IHC. Tumors identified all while tumor uptake peaked 4 hr, T:B plateaued 48-72 hr. Conclusions vivo humans can imaged without addition cold Herceptin. Based RDRC recommendations, 3.5 mCi/dose would permit three within 1 year